ABEO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABEO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Abeona Therapeutics's interest expense for the three months ended in Dec. 2023 was $ -0.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.42 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Abeona Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -13.21 Mil. Abeona Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -0.11 Mil. Abeona Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Abeona Therapeutics's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -0.40 | -4.12 | -3.66 | -0.74 | -0.42 |
Abeona Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Interest Expense | Get a 7-Day Free Trial | -0.18 | -0.10 | -0.10 | -0.11 | -0.11 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (NAS:ABEO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Abeona Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-0.11 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-13.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $4.40 Mil.
Abeona Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
Abeona Therapeutics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Mark Alvino | director | C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019 |
Michael Amoroso | officer: Chief Operating Officer | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
Vishwas Seshadri | director, officer: Chief Executive Officer | 64 STRYKER COURT, BRIDGEWATER NJ 08807 |
Leila Alland | director | C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512 |
Christine Berni Silverstein | officer: Chief Financial Officer | C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Joseph Walter Vazzano | officer: Chief Financial Officer | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Brendan M. O'malley | officer: SVP, General Counsel | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Adage Capital Partners, L.p. | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Adage Capital Management, L.p. | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Adage Capital Partners Gp, L.l.c. | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Robert Atchinson | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Phillip Gross | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Edward Carr | officer: Vice President, Controller | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Todd Wider | director | 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219 |
From GuruFocus
By Marketwired • 07-07-2023
By Marketwired • 08-30-2023
By sperokesalga sperokesalga • 05-11-2023
By sperokesalga sperokesalga • 05-22-2023
By GuruFocusNews GuruFocusNews • 06-08-2022
By Marketwired • 09-26-2023
By GuruFocusNews GuruFocusNews • 06-26-2022
By Marketwired • 07-28-2023
By Marketwired • 07-03-2023
By GuruFocusNews GuruFocusNews • 06-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.